View:
Download DOC
Download PDF
Download XLS
Download XBRL
crvo20240105_8k.htm
false 0001053691 0001053691 2024-01-05 2024-01-05
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
 
FORM 8-K
___________________________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
January 5, 2024
Date of Report (Date of earliest event reported)
___________________________
 
CervoMed Inc.
(Exact name of registrant as specified in its charter)
___________________________
 
Delaware
  
001-37942
  
30-0645032
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)
   
20 Park Plaza, Suite 424
Boston, Massachusetts
  
02216
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (617) 744-4400
 
Not applicable
(Former name or former address, if changed since last report)
___________________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.001 par value
  
CRVO
  
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
Item 8.01         Other Events
 
On January 5, 2024, CervoMed Inc. (the “Company”) issued a press release announcing that members of the Company’s senior management team will present at the Emerging Growth Conference 66 on Thursday, January 11, 2024 at 11:25 a.m. ET. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01         Financial Statements and Exhibits
 
(d)         Exhibits
 
Exhibit No.
  
Description
     
99.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: January 5, 2024
CervoMed Inc.
 
By:         /s/ William Elder__________
Name:    William Elder
Title:       General Counsel
 
 
 
ex_612618.htm

Exhibit 99.1

 https://cdn.kscope.io/9f6e17e827d12716f5a9444e0acc3335-a01.jpg

 

CervoMed to Participate in the Emerging Growth Conference 66

 

Boston – January 5, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will provide a corporate update at the Emerging Growth Conference 66, to be held virtually from January 10-11, 2024.

 

Presentation Details

Format: Corporate presentation

Date: Thursday, January 11, 2024

Time: 11:25 AM ET

Registration Link: click here

 

A live webcast of the presentation, along with accompanying slides, will be accessible here. A replay of the presentation will also be available through the conference portal and on the Emerging Growth YouTube Channel following the event.

 

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

 

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

 

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

 

About CervoMed

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

 

Investor Contact:

PJ Kelleher

LifeSci Advisors

Investors@cervomed.com

617-430-7579